Needham analyst Ami Fadia initiated coverage of Mirati Therapeutics with a Hold rating and no price target. Despite the recent pullback, Fadia struggles to see a path to near-term upside, the analyst tells investors in a research note. Last week’s ESMO update puts into question adagrasib’s likelihood of success in 1L NSCLC, particularly in TPS greater than or equal to 1%, the analyst adds.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
